• PRO
  • Events
  • About Blog Store Popular
  • Login
  • Register
  • PRO
  • Resources
    • Latest updates
    • Q&A
    • In-depth
    • In-house view
    • Practical resources
  • Resources
  • Research
    • Legal research hub
    • Primary Sources
    • Research reports
    • Explore all
  • Research
  • Learn
    • All
    • Webinars
    • Videos
  • Learn
  • Experts
    • Find experts
    • Influencers
    • Firms
    • About
    Introducing Instruct Counsel
    The next generation search tool for finding the right lawyer for you.
  • Experts
  • My newsfeed
  • Events
  • About
  • Blog
  • Store
  • Popular
  • Legal research hub
  • Primary Sources
  • Research reports
  • Explore all
  • Find experts
  • Influencers
  • Firms
  • About
Introducing Instruct Counsel
The next generation search tool for finding the right lawyer for you.
  • Compare
  • Topics
  • Interviews
  • Guides

ANALYTICS

Review your content's performance and reach.

  • Analytics dashboard
  • Top articles
  • Top authors
  • Who's reading?

Content Development

Become your target audience’s go-to resource for today’s hottest topics.

  • Trending Topics
  • Discover Content
  • Horizons
  • Ideation

Client Intelligence

Understand your clients’ strategies and the most pressing issues they are facing.

  • Track Sectors
  • Track Clients
  • Mandates
  • Discover Companies
  • Reports Centre

Competitor Intelligence

Keep a step ahead of your key competitors and benchmark against them.

  • Benchmarking
  • Competitor Mandates
Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Linked In
  • Follow
    Please login to follow content.
  • Like
  • Instruct

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Register now for your free, tailored, daily legal newsfeed service.

Questions? Please contact [email protected]

Register

FDA continues scrutiny of DTC genetic testing by clinical labs

Sidley Austin LLP

To view this article you need a PDF viewer such as Adobe Reader. Download Adobe Acrobat Reader

If you can't read this PDF, you can view its text here. Go back to the PDF .

USA November 17 2015

The U.S. Food and Drug Administration (FDA) recently released three untitled letters from the Office of In Vitro Diagnostics and Radiological Health (OIR) to clinical laboratories offering direct-to-consumer (DTC) genetic tests, and a report of case studies purporting to provide public health evidence for FDA oversight of all laboratory-developed tests (LDTs). The three letters allege that the laboratories in question were offering medical devices that required premarket review by FDA. The letters came less than two months after a similar letter in late September. This all shows that OIR is still actively engaged in its effort to assert greater control over clinical laboratories generally, and genetic testing in particular, despite recent legislative efforts to limit this authority and FDA’s recent authorization of a DTC genetic test offered by 23andMe.

The three letters, sent to DNA4Life, DNA-Cardiocheck, Inc. and Interleukin Genetics, Inc., all concerned tests intended to identify patients at increased risk for certain medical conditions or drug responses. The September letter to Pathway Genomics, Inc. alleged that the company’s genetic tests for early cancer detection and the blood collection tubes mailed to consumers were medical devices requiring premarket review. 

FDA has not traditionally regulated LDTs — in vitro diagnostics intended for clinical use and designed, manufactured and used within a single laboratory. But FDA has long maintained that the unregulated status of LDTs is a result of the agency’s decision to refrain from invoking its medical device authorities, rather than a consequence of the agency’s lack of statutory authority over LDTs. 

FDA has taken steps in recent years to assert authority over LDTs, particularly those that are DTC genetic tests. In 2010 and 2011, FDA issued at least 20 untitled letters targeting DTC genetic tests. In 2014, FDA further proposed a framework for regulatory oversight of all LDTs, which stated that LDTs marketed DTC are subject to regulation as medical devices and not eligible for enforcement discretion.1 On November 16, FDA’s Office of Public Health Strategy and Analysis released a reportcalling for additional oversight of LDTs, describing 20 examples of tests that “may have caused or have caused actual harm to patients” due to the absence of compliance with FDA requirements. More than half of the examples involve genetic testing.2

A coalition of manufacturers and two physician specialty societies have responded by proposing legislative text that would limit FDA’s authority over LDTs, and the House of Representatives Committee on Energy and Commerce recently issued a discussion draft of such legislation. “Precision medicine” proposals, focused on the development of personalized therapies and diagnostics, have also been included in several bills introduced in Congress. Finally, FDA itself issued a de novo decision letter authorizing 23andMe to market genetic carrier tests DTC after asking the company to stop marketing those and other genetic tests in a November 2013 warning letter.


Some clinical laboratories seeking to offer DTC genetic tests might have viewed these developments as evidence that FDA’s approach has softened in light of uncertain federal policy. The recent letters and report signal that FDA remains focused on such tests and willing to assert authority over them.

To view all formatting for this article (eg, tables, footnotes), please access the original here.
Sidley Austin LLP - Coleen Klasmeier, Torrey Cope and Andrew R. Van Haute
Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Linked In
  • Follow
    Please login to follow content.
  • Like
  • Instruct

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Filed under

  • USA
  • Healthcare & Life Sciences
  • Sidley Austin LLP

Tagged with

  • Food and Drug Administration

Popular articles from this firm

  1. White House Unveils Expansive Infrastructure Proposal *
  2. A general introduction to the regulation of virtual currencies in USA *
  3. White House Environmental Justice Advisory Council Holds First Meeting *
  4. In review: commercial contract interpretation in USA (California) *
  5. In review: commercial contract interpretation in USA (New York) *

If you would like to learn how Lexology can drive your content marketing strategy forward, please email [email protected].

Powered by Lexology
loading...

Related research hubs

  • USA
  • Healthcare & Life Sciences
Sonja Sarantis
Legal Counsel
State Street Bank and Trust Company
What our clients say

"An excellent service!"

Back to Top
Resources
  • Daily newsfeed
  • Q&A
  • Research hubs
  • Learn
  • In-depth
Experts
  • Find experts
  • Legal Influencers
  • Firms
  • About Instruct Counsel
More
  • About us
  • Blog
  • Events
  • Store
  • Popular
Legal
  • Terms of use
  • Cookies
  • Disclaimer
  • Privacy policy
  • GDPR compliance
Contact
  • Contact
  • RSS feeds
  • Submissions
 
  • Login
  • Register
  • Follow on Twitter
  • Follow on LinkedIn

© Copyright 2006 - 2021 Law Business Research

Law Business Research